Argobio and GeneCode Partner on Parkinson’s Disease in Argobio’s First Announced Research Agreement
Argobio and GeneCode have announced their collaboration to develop small molecule Glial cell line - Derived Neurotrophic Factor (GDNF) mimetics for the treatment of Parkinson’s Disease and other indications.
In the venture studio model developed by Argobio, breakthrough technologies are embraced by a team of scientific experts with an entrepreneurial and industrial experience. Over the course of incubation, Argobio will fund the project development up to 3 ME and incorporate the start-up. After incubation, further venture funding will be provided by specialized VC investors.
“The launch of our first collaboration is a great achievement for Argobio. Argobio intends to incubate until series A at least five projects in the fields of rare diseases, neurosciences, and oncology over the next three years. With a committed capital of €50 million, and a team of pharma industry experts, Argobio expects to deliver strong projects, well-prepared for Series A funding,” Thierry Laugel Argobio Chairman said.
GeneCode, a discovery-stage biotech company developing small molecule GDNF mimetics, in collaboration with the laboratory of Mart Saarma, Professor and Research Director of the Institute of Biotechnology, HI-LIFE, University of Helsinki, Finland, has identified and patented a series of small molecules activating the GDNF signalling receptor RET tyrosine kinase. Professor Saarma´s team has discovered GDNF receptors, clarified the GDNF-receptor structure and investigated the therapeutic potential of GDNF family members.
Professor Mart Saarma commented, “Argobio’s investment and participation in the development of effective GDNF mimetics is extremely encouraging news. GDNF mimetics can overcome the limitations of the GDNF protein and can open up a completely new page in the treatment of Parkinson’s disease.”
GeneCode CEO Paavo Pilv added, “ Our combined expertise will catapult this technology beyond what we would have been able to achieve alone. Considering the pivotal role of GDNF family ligands and RET signalling pathways for other groups of cells, applications of compounds developed by GeneCode are not limited only to Parkinson’s Disease but can be applied to treat other medical conditions.”
“We have ambitious goals for the next two years,” Argobio Entrepreneur in Residence Yves Ribeill, PhD said. “The whole is greater than the sum of the parts with the combined, diverse expertise of GeneCode, Argobio and Professor Saarma. I am confident that we will be able to demonstrate that the unique business model of funded partnerships initiated by Argobio in Europe will give new therapeutics a boost to succeed.”
About Argobio: www.argobiostudio.com
Argobio is a start-up studio based in Paris, France, dedicated to turning cutting-edge innovations into breakthrough biotech companies. Argobio sources innovative early-stage projects on therapeutics from renowned European academic research institutions with a focus on rare diseases, neurological disorders, oncology, and immunology. Argobio selects and incubates these projects with the goal to create biotech companies and develop (or lead) them up to a significant Series A financing. Argobio provides broad expertise in the discovery and development of novel drugs with a team of highly experienced Biotech entrepreneurs. The internal team is led by Yves Ribeill, Neill Mackenzie and Rémi Soula. Thierry Laugel, Managing Partner at Kurma Partners is the President of Argobio.
Follow us on LinkedIn.
About GeneCode: www.GeneCode.com
GeneCode is a private pharmaceutical development company focused on the development of disease-modifying therapeutics to combat neurodegeneration. The GDNF Mimetics platform leverages the disease-modifying properties of GDNF to small molecules with drug-like properties.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211216005337/en/
Contact information
NewCap – Media relations:
Nicolas Merigeau – nmerigeau@newcap.fr – +33 1 44 71 94 98
Arthur Rouillé – arouille@newcap.fr – +33 1 44 71 00 15
Argobio:
Yves Ribeill – yves.ribeill@argobiostudio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
World FZO Brings Its 12 th World Congress to Panama in 202631.7.2025 10:00:00 EEST | Press release
The World Free Zones Organization announced the signing of a Memorandum of Understanding with the government of Panama to host the 12th annual World FZO’s World Congress in the country’s capital, Panama City, in July 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250731827900/en/ H.E. Dr. Al Zarooni Signing the MoU with the Minister of Commerce and Industries in Panama (Photo: AETOSWire) The MoU was signed by His Excellency Dr. Mohammed AlZarooni, Chairman of the World FZO, and His Excellency Julio Moltó, Minister of Commerce and Industries at the Government of the Republic of Panama, in the presence of senior officials from both sides. The announcement was made during an official visit led by Dr. AlZarooni to Panama City, where he met with His Excellency José Raúl Molino Quintero, President of the Republic of Panama. On the sidelines of the visit, the delegation toured key sites in Panama, including the Colón Free Tra
SES Delivers Solid H1 2025 Results & Completes Intelsat Acquisition31.7.2025 08:30:00 EEST | Press release
SES S.A. completed Intelsat acquisition on 17 July 2025 and announces financial results for the six months ended 30 June 2025. H1 2025 solid performance – reiterating FY25 outlook Revenue of €978 million (-0.2% yoy(1)) and Adjusted EBITDA(2) of €521 million (-0.7% yoy(1)) Networks (+10.3% yoy(1)) supported by +17.1% yoy(1) growth in Government and +9.5% yoy(1) growth in Mobility; Media (-12.1% yoy(1)) in-line with expectations with important new long-term renewals signed €690 million of new business and contract renewals signed in H1 2025 – with a total gross contract backlog of €4.2 billion Adjusted FCF of €193 million (+32.0% yoy) and Net Leverage at 1.1 times(3) (including cash & cash equivalents of €4.3 billion(4)) O3b mPOWER satellites 7&8 in service since May; 9&10 successfully launched 22 July – boosting O3b mPOWER network capacity and resilience SES and Luxembourg Government to develop and launch new defence satellite for GovSat FY 2025 financial outlook(5) well on track, reite
AB InBev Reports Second Quarter 2025 Results31.7.2025 08:02:00 EEST | Press release
Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250730542419/en/ AB InBev's three strategic pillars. Regulated information1 “Beer is a passion point for consumers. The resilience of the beer category and the continued momentum of our megabrands delivered another quarter of profitable growth. EBITDA increased by 6.5% and the ongoing optimization of our business drove Underlying EPS growth of 8.7%. While the operating environment remains dynamic, the consistent execution of our strategy by our teams and partners drove a solid first half of the year and reinforces our confidence in delivering on our outlook for 2025.” – Michel Doukeris, CEO, AB InBev Revenue +3.0% Revenue increased by 3.0% in 2Q25 with revenue per hl growth of 4.9% and by 2.3% in HY25 with revenue per hl growth of 4.3%. Reported revenue decreased by 2.1% in 2Q25 to 15 004 million USD and by 4.2%
Azelis Delivers 11% Free Cash Flow Growth in H1 202531.7.2025 08:00:00 EEST | Press release
Azelis (Brussels:AZE): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250730152197/en/ Highlights H1 2025 Revenue of EUR 2.2bn in H1 2025, representing year-on-year increase of 0.6% (+3.3% on a constant currency basis), with 1.2% organic revenue growth and 2.2% revenue growth contribution from acquisitions offsetting the negative F/X impact during the period. Gross profit of EUR 515m resulting in gross profit margin of 23.9%. The 68 bp gross margin contraction reflects the mix effect from higher growth contribution from Industrial Chemicals and the Group's less mature businesses. Adjusted EBITA of EUR 234m results in adjusted EBITA margin of 10.9%, and conversion margin of 45.5%. The EBITA and conversion margins do not yet reflect the full benefit of cost savings measures announced at the beginning of Q2. Net profit of EUR 85m represents a decline of 14.6% over the prior year, driven by the lower operating profit. Free cash
Tigo Energy TS4 Flex MLPE Device Family Certified Compatible With Haier Energy Inverters31.7.2025 07:00:00 EEST | Press release
Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, has signed a certificate of compatibility with Haier Energy, documenting the compatibility between Tigo Flex MLPE products and hybrid solar inverters from Haier. The certification covers certain single-phase and three-phase Haier products and members of the Tigo TS4 product family, when properly designed and installed. Together, these products are designed to deliver high-quality and enhanced value with a system that generates and manages solar energy more efficiently and helps deliver the features residential energy customers demand. "We are very proud to share the compatibility with a trusted partner like Tigo Energy,” said Federica Cona, EU product manager at Haier Energy. “This collaboration completes our technical product range and gives installers the flexibility to use our solutions across all plant conditions with full adaptability." Solar installers in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom